(+)-Borneol improves the efficacy of edaravone against DSS-induced colitis by promoting M2 macrophages polarization via JAK2-STAT3 signaling pathway.

Compound edaravone injection (C.EDA), a compound preparation composed of edaravone (EDA) and (+)-Borneol with the mass ratio of 4: 1, displays a better anti-inflammatory activity than EDA. However, its precise mechanism remains to be further studied. In this work, we investigated whether (+)-Borneol could improve the efficacy of EDA against DSS-induced colitis. We found that C.EDA at 7.5 and 15mg/kg could significantly relieve the disease activity index (DAI) and reduce the loss of body weight and colon length in a dose-dependent manner, while EDA or (+)-Borneol alone only had moderate effects even at the highest dose. Additionally, ELISA revealed that C.EDA could more dramatically decrease the protein levels of inflammatory cytokines and increase the levels of anti-inflammatory cytokine than EDA or (+)-Borneol alone both in colon tissues and serum. H&E staining and IHC assay also indicated that C.EDA exhibited more prominent effects on increasing the population of M2 macrophages, decreasing M1 macrophages infiltration and protecting intestinal barrier integrity. Furthermore, in vitro studied demonstrated that C.EDA, EDA or (+)-Borneol failed in inhibiting M1 macrophages activation but could specifically induce the activation of M2 macrophages in a STAT3-dependent manner. Knockdown the expression of STAT3 successfully abolished the effect of C.EDA and EDA on promoting M2 macrophages activation. Consistent with in vivo study, C.EDA exhibited a more efficient ability of inducing M2 macrophages polarization and STAT3 activation than EDA or (+)-Borneol alone in vitro. In conclusion, we confirmed that (+)-Borneol improved the efficacy of EDA against DSS-induced colitis by promoting M2 macrophages polarization via JAK2-STAT3 signaling pathway.

Influence of Trisialoganglioside-GT1b combined with Edaravone Injection on clinical effect and serum related indicators in patients with acute cerebral infarction / 药物评价研究

Objective To investigate the influence of Trisialoganglioside-GTlb combined with Edaravone Injection on clinical effect and serum related indicators in patients with acute cerebral infarction.Methods A total of 126 cases of patients with acute cerebral infarction in our hospital from October 2010 to May 2016 were selected and divided into observation group and control group,63 cases in each group.Patients in the control group were treated with regular treatment and Edaravone Injection,and patients in the observation group were treated with regular treatment,Edaravone Injection and Trisialoganglioside-GTlb.The clinical effect,NIHSS scores,Barthel index scores,serum level of neuron specific enolase (NSE),S100β protein,superoxyde dismutase (SOD),advanced oxidation protein products (AOPP) and malondiadehyde (MDA) were compared.Results The total effective rate of the observation group (90.48％) was significantly higher than that of the control group (76.19％),the difference between the two groups was statistically significant (P ＜ 0.05).After two weeks of treatment,two groups of NIHSS and Barthel index scores were significantly lower than before treatment,the difference was statistically significant (P ＜ 0.05);and the NIHSS and Barthel index scores of observation group were significantly lower than that of control group,the difference was statistically significant (P ＜ 0.05).NIHSS scores,Barthel index scores of the observation group were significantly better than that of the control group (P ＜ 0.05);The serum level of NSE,S100,AOPP,MDA of two groups after treatment were significantly lower than that before treatment,the difference was statistically significant (P ＜ 0.05);and the above indexes of the observation group was significantly lower than the control group,the difference was statistically significant (P ＜ 0.05);SOD levels of two groups were significantly increased than before treatment,the difference was statistically significant (P ＜ 0.05);and the SOD levels of observation group was significantly higher than that of control group,the difference was statistically significant (P ＜ 0.05).Conclusion Trisialoganglioside-GT1b can synergy improve the clinical effect of Edaravone Injection in patients with acute cerebral infarction,and be good to recovery the neurologic function and ability of daily living,and these may be related to the change of the serum level of NSE,S100β protein,SOD,AOPP and MDA.

The influence of edaravone on cognitive ability in patients with vascular dementia / 中国基层医药

Objective To observe the influence of edaravone on the cognitive ability in patients with vascular dementia(VD).Methods 70 cases with mild to moderate VD were randomly divided into observation group( edaravone treatment) and control group( piracetarn treatment),35 cases in each group.Treatment cycle was two weeks.The scores of MMSE,CDT,MoCA were compared before and after treatment between the two groups.Results The scores were found to be significantly higher after use edaravone in the observation group ( t =4.21,1.45,12.37,all P ＜0.05 ).The score had no difference before and after treatment in the control group ( P ＞ 0.05 ).Conclusion Edaravone could improve cognitive abilitys in VD patients through its function of anti-oxidant and free-radical scavenging.

Effects of Shuxuetong injection combined with edaravone injection on neurological, sermn lipid, C-reactive protein and interleukin 6 levels in serum of patients with acute cerebral infarction / 国际中医中药杂志

Objective To observe effects of shuxuetong injection combined with edaravone injection on the neurological, sermn lipid, c-reactive protein and interleukin 6 Levels in serum in patients with acute cerebral infarction. Methods 100 patients with acute cerebral infarction were randomly recruited into a control group and a treatment group by means of random number table. The control group was treated with 30mg edaravone injection, which was added to 100 ml normal saline, twice a day, continuous therapy for 14 days, and the treatment group was treated with 6mg shuxuetong injection, which was added to 2S0 ml normal saline, once a day, continuous therapy for 14 days based on the control group. The neurological was observed, triglyceride (TG) , cholesterol (TO , low density lipoprotein cholesterol (LDL-C) , high density lipoprotein cholesterol (HDL-C) , c-reactive protein and interleukin 6 Levels in serum were detected before and after the treatment.Results Compared with the control group, neurological deficit score, c-reactive protein and interleukin 6 Levels in serum in the treatment group decreased significantly (χ2=4.351, 3.81, 3.617 respectively, P<0.05) .TG, TC, LDL-C in serum in the treatment group were lower than that of the control group (χ2=2.135,P<0.01; χ2=3.061, 3.655, P<0.05 ); HDL-C in serum was higher than that of the control group (χ2=2.762,P<0.01) . The total effective rate of the treatment group and the control group was 86.0% and 66.0% respectively, there was a significant difference (χ2=3.393, P<0.05) . Conclusion Shuxuetong injection combined with edaravone injection is better than edaravone injection to treat acute cerebral infarction.

Effects of Ginkgo Bilobate Extract Injection on the hemorheology, blood lipid and C-reactive protein in serum of patients with cerebral infarction / 国际中医中药杂志

ObjectiveTo observe effects of ginkgo bilobate extract injection on the hemorheology,blood lipid and c-reactive protein in serum of patients with cerebral infarction. Methods62 cases patients with cerebral infarction were randomly divided into two groups by means of random number table. Two groups were both given routine treatment. The control group was treated with 20ml compound salvia injection, which was added to 250 ml normal saline, once a day, continuous therapy for 14 days, and the treatment group was treated with 20ml ginkgo bilobate extract injection, which was added to 250 ml normal saline, once a day, continuous therapy for 14 days. The clinical symptoms were observed, hemorheology related index, level of blood lipid and c-reactive protein were detected before and after the treatment. ResultsCompared with the control group,hemorheology related index decreased significantly in the treatment group, especially whole blood viscosity ( 1.57±0.28) mpa ·s (P＜0.01). Blood reduced viscosity (13.95 ± 2.07) mpa ·s, erythrocyte aggregation index (1.37±0.12) , hematocrit (42.36±8.16) were also decreased significantly (P＜0.05) .Triglyceride (TG)(1.23±0.12) mmol/L、 cholesterol (TC) (4.29±1.17) mmtmol/L、 low density lipoprotein cholesterol (LDIL-C)(2.31± 0.39) mmol/L and c-reactive protein ( 10.48 ±- 3.82) mg/L in serum in the treatment group were lower than those of the control group (P＜0.01 orP＜0.05) , high density lipoprotein cholesterol (HDL-C) ( 1.78±0.76) mmol/L in serum was higher than that of the control group (P＜0.01) .The total effective rate of the treatment group and the control group was 87.1％ and 67.7％ respectively, there was a significant difference (x2=3.553, P＜0.05). Conclusion The ginkgo bilobate extract injection can protect cerebral infarction from injury,which may be related with its action on regulating the blood viscosity and level of blood lipid.

Clinical Observation on the treatment of 58 cases of acute cerebral infarction with Danhong injection combined with Edaravone injection / 国际中医中药杂志

Objective To observe clinical effect of treating acute cerebral infarction with Danhong injection combined with Edaravone injection. Methods 58 cases with acute cerebral infarction were randomly recruited into a control group and a treatment group. The control group was treated with edaravone injection, 30 mg, once daily, and for continuous 14 days. The treatment group was treated with dan hong injection, 20 ml, once daily, and for continuous 14 days based on the control group. The clinical effect and adverse reaction were observed in both groups after the treatment. Results The total effective rate was 86.2% and 62.1% in the treatment group and the control group respectively. The clinical effect in the treatment group was significantly higher than that of the control group (χ2=3.561, P＜0.05). Conclusion Danhong injection combined with edaravone injection was more effective in treating acute cerebral infarctionthan edaravone injection exclusively.

Determination of Edaravone Contents in Injection by RP-HPLC / 中国药房

OBJECTIVE:To establish a method for determination of Edaravone cont en ts in injection METHODS:The Kromasil C18 column(4 6mm?200mm,5?m) was use d The mobile phase was consisted of 0 1mol/L NaH2PO4-methanol(45∶55) with detection at 242nm,flow rate was 1 0ml/min RESULTS:The linear range was 1 2 4?g/ml～24 8?g/ml(r=0 9 999),the mean recovery was 100 3% with RSD=0 9 5%(n=6) CONCLUSION:This method is simple,sensitive and accurate,and can b e used to control the quality of Edaravone injection